BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
I'm PortAI, I can summarize articles.
MELVILLE, N.Y., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- BioRestorative Therapies, Inc. ( "BioRestorative", "BRTX" or the "Company" ) ( NASDAQ:BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has been granted a Type B meeting with ...
Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments